THURSDAY, AUGUST 17, 2017

Visterra collaborates with A*STAR to make monoclonal antibody for dengue

Visterra collaborates with A*STAR to make monoclonal antibody for dengue | Courtesy of wikipedia.org

Visterra Inc., a clinical-stage biotechnology company with a unique technology platform to discover disease targets and create novel treatments for infectious diseases, and the Agency for Science, Technology and Research’s (A*STAR) Drug Discovery and Development (D3) unit, recently partnered to create VIS513 -- Visterra’s treatment that uses broadly neutralizing antibodies to fight dengue fever.

“This collaboration illustrates D3’s goal of bringing innovative early-stage research that addresses unmet medical needs in Singapore to proof-of-concept clinical trials in humans,” Chief Executive Officer of D3 and A*STAR’s Experimental Therapeutics Centre Alex Matter said. “We are encouraged by VIS513’s preclinical data, which demonstrate its potential to broadly neutralize all four dengue virus serotypes, as there is currently no specific treatment for dengue, and prevention depends solely on limiting or eradicating mosquitoes that transmit the virus. We are looking forward to working closely with Visterra and advancing VIS513 into the clinic.”

Brian Pereira, president and CEO of Visterra, said he is delighted to enter into this collaboration with D3, enabling them to use the capabilities, infrastructure and emerging infectious diseases expertise in Singapore to bring their promising antibody for dengue fever, VIS513, from preclinical to clinical development.

"Visterra’s has deep roots in Singapore because of our long-standing association with the Infectious Disease Interdisciplinary Group of the Singapore-MIT Alliance for Research and Technology (SMART) Centre, which has made important contributions by advancing our scientific understanding of dengue fever and the potential role of antibodies to combat the virus,” Pereira said.